Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new research published in Cell.
Current seasonal influenza vaccines mainly target a different, more abundant influenza surface protein called hemagglutinin (HA). However, because influenza vaccines offer varying and sometimes limited protection, scientists are exploring ways to improve vaccine effectiveness. The new research builds on previous studies of NA and was conducted by a team of scientists including investigators from the Centers of Excellence for Influenza Research and Surveillance (CEIRS)program, which is organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Investigators analyzed blood samples from people vaccinated against influenza and people diagnosed with either the 2009 H1N1 influenza virus or H3N2 influenza viruses. The volunteers were recruited for this study or had taken part in prior influenza research studies. The analyses indicate that influenza vaccines rarely induce NA-reactive antibodies, whereas natural influenza infection induces these types of antibodies at least as often as they induce HA-reactive antibodies. Additional studies in mice reinforced the human data, indicating that current influenza vaccines do not induce NA-reactive antibodies efficiently.
Additional laboratory experiments show that the NA-reactive antibodies induced during natural influenza infection are broadly reactive, meaning they could potentially protect against diverse strains of influenza. To test this theory, scientists isolated NA-reactive monoclonal antibodies from the H3N2 and H1N1 influenza patients (N2-reactive antibodies and N1-reactive antibodies, respectively). They administered 13 N2-reactive antibodies to mice and subsequently infected the mice with a different H3N2 virus strain. Eleven of the 13 N2-reactive antibodies partially or fully protected the mice. They also administered eight N1-reactive antibodies to mice and subsequently infected the mice with a similar H1N1 virus strain or an H5N1-like virus strain. Four of the eight antibodies completely protected the mice against both virus strains.
The authors note that the findings suggest that influenza vaccines should be optimized to better target NA for broad protection against diverse influenza strains. In this regard, NIAID is supporting research to characterize NA responses in infected and vaccinated individuals and to determine the mechanism of action of NA protection. NIAID also supports “NAction!” a CEIRS working group that identifies knowledge gaps in our understanding of NA and sets NA research priorities for improved influenza vaccines. These efforts contribute to NIAID’s larger plan to develop a universal influenza vaccine—a vaccine that can durably protect all age groups against multiple influenza virus strains.
The Latest on: Influenza
via Google News
The Latest on: Influenza
CDC’s ACIP discusses vaccines for influenza, HPV, and more
on July 10, 2018 at 7:12 am
CDC’s Advisory Committee on Immunization Practices (ACIP) met in Atlanta on June 20–21 to review a variety of immunization topics, including influenza, HPV, and more. ACIP’s recommendations aren’t off... […]
Influenza Diagnostics Market 2018 Global– Key Players, Size, Trends, Growth- Analysis to 2023
on July 10, 2018 at 6:51 am
Pune, India -- (SBWIRE) -- 07/10/2018 -- Market Scenario: Global Influenza Diagnostics Market is growing moderately. Influenza or flu is one of the common medical condition which occur in seasonal epi... […]
Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine
on July 9, 2018 at 9:51 am
ORLANDO, Fla., July 09, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen® i... […]
CHP investigates a fatal case of paediatric influenza A infection
on July 9, 2018 at 6:12 am
Hong Kong (HKSAR) - The Centre for Health Protection (CHP) of the Department of Health is today (July 9) investigating a fatal case of paediatric influenza A infection. The nine-year-old girl, with un... […]
Zimbabwe: Common Cold, Influenza Kill 12
on July 9, 2018 at 3:17 am
At least 12 people have died of common cold and influenza in the country this year while 9 962 cases of the diseases have been reported in one week countrywide. According to the recent weekly surveill... […]
Vinh Long: A/H1N1 influenza kills one woman
on July 7, 2018 at 11:39 pm
The swine flu virus A/H1N1 has left a female dead in the Mekong Delta province of Vinh Long after a male patient died at a medical centre in Tran Van Thoi district of Ca Mau province earlier this mont... […]
Anti-Influenza Vaccination Coverage Increases in Bolivia
on July 6, 2018 at 9:20 pm
07 de julio de 2018, 00:05La Paz, Jul 7 (Prensa Latina) Bolivian Health Minister Rodolfo Rocabado reported that influenza vaccination coverage in the country is currently at 50 percent. We have a nati... […]
Simple Precautions Can Help Protect People From Influenza
on July 3, 2018 at 11:15 am
Typically we think of flu-season happening during the winter months, when the weather is cold and people are inside. However, sometimes we do see the spread of influenza virus during the summer months ... […]
500 Million Year Old Gene Could Mean A Path To New Treatments For Influenza, Arthritis - And You Can Help Name It
on July 2, 2018 at 12:03 pm
A gene called called C6orf106, or "C6", has existed for 500 million years, but understanding how it controls the production of proteins involved in infectious diseases, cancer and diabetes is only bei... […]
via Bing News